生命科学资讯

Sarepta CEO Doug Ingram to retire after a decade of Duchenne breakthroughs and controversies

Analysts see potential in MDMA drug after AtaiBeckley reports improvements in anxiety trial

UBS Group Lowers Agilent Technologies (NYSE:A) Price Target to $165.00 - MarketBeat

Senate hearing raises FDA-related concerns for new rare disease drugs

Agilent Technologies shares fall after Q1 earnings miss - Investing.com

Viatris plans to lay off up to 10% of staff, discloses Indian factory fire

Did Thermo Fisher’s (TMO) 10% Dividend Hike After Earnings Beat Just Reframe Its Capital Return Story? - simplywall.st

Agilent Technologies (A): Wells Fargo Lowers Price Target to $16 - GuruFocus

THERMO FISHER SCIENTIFIC INC. SEC 10-K Report - TradingView

Lilly’s GLP-1 pill tops Novo’s Rybelsus in head-to-head trial

Why did my doctor push Grail’s dubious cancer test?

Appointments and advancements for Feb. 26, 2026

Financings for Feb. 26, 2026

In the clinic for Feb. 26, 2026

Other news to note for Feb. 26, 2026

Regulatory actions for Feb. 26, 2026

Thermo Fisher Scientific Inc. (NYSE:TMO) Announces Quarterly Dividend of $0.47 - MarketBeat

Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer

AtaiBeckley stock drops on Phase 2a data; Disc to refile rare disease drug

Boehringer pens $500M pact with British biotech for oral approach to autoimmune diseases